QUANTITATION OF HCV RNA IN LIVER OF PATIENTS WITH CHRONIC HEPATITIS C

Ana de Lôurdes Candolo MARTINELLI1,4, David BROWN1, Allun MORRIS1, Amar DHILLON2, Peter DAYLEY3 and Geoffrey DUSHEIKO1

ABSTRACT - Background/Aims - Liver HCV RNA has been quantitated in few studies and the feasibility and the role of this parameter in the evaluation of patients with chronic HCV hepatitis still warrant study. Our aim was to determine the concentrations of HCV RNA in the liver of chronic HCV patients and to correlate the results with serum viral load. We also studied the relation of levels of HCV RNA in the liver with serum aminotransferases levels and with the presence of cirrhosis.

Methods - Twenty patients (14 males, aged 28 to 61 years) were studied. Twelve were infected by HCV type 1, six by type 3 and one by type 5. Percutaneous liver biopsy samples were obtained from 14 patients, and the remainder from liver explant in patients undergoing OLT. Twelve had chronic hepatitis and eight cirrhosis. HCV RNA levels were determined by bDNA.

Results - HCV RNA levels below the detection limit were found in one liver and in five serum samples. HCV RNA (mean ± SD) was 2.1 x 10^8 ± 2.2 x 10^8 Eq/gm in the liver and 94 x 10^5 ± 93 x 10^5 Eq/mL in serum, with a significant correlation between these values (r = 0.89; P < 0.0001). Serum HCV RNA levels were significantly lower (P = 0.001) in cirrhotic than in chronic hepatitis patients, while the groups did not differ in liver HCV RNA levels. No correlation was observed between liver or serum HCV RNA and serum ALT or AST. Conclusions - Quantitation of HCV RNA is possible even in small liver samples. Although average levels are more than one log higher than those observed in serum, hepatic concentrations correlate with those observed in serum. The application of this technology to monitoring antiviral therapy and understanding the pathogenesis of the disease remains to be determined.

INTRODUCTION

The mechanisms mediating hepatocellular injury in chronic hepatitis C infection are not completely clear. Evidence suggests that both a direct viral cytopathic injury and immunologically mediated hepatocellular damage occur (15, 16, 18). The role of the level of HCV RNA in serum in affecting the progression of hepatitis and its prognosis is still unclear (20). However, higher levels of HCV RNA are associated with lower rate of response to interferon therapy (4, 7, 19, 20). In addition, some HCV virus genotypes can be associated with higher viraemia levels (5, 8, 11). Quantitative evaluation of serum HCV RNA appears to be of importance in the management of the patient (9) and it has been suggested as a parameter to decide what doses of IFN should be employed (31).

It is assumed that liver concentration reflects serum concentration. However, there are few studies in which HCV RNA has been simultaneously quantitated in serum and liver samples (1, 6, 10, 14, 17). Moreover, the disease is complex, and both hepatic and extrahepatic sites of replication may contribute to the viral levels observed in serum. In addition, the relation between liver HCV RNA viral load and activity or stage of the liver disease remains unclear.

The objectives of the present work were to assess the feasibility of measuring HCV RNA levels in small tissue samples from percutaneous liver biopsies and to study their correlation with the serum levels of HCV RNA in patients with chronic HCV liver disease. Additionally we evaluated the relation of viral load with the serum levels of aminotransferases and with the presence of hepatic cirrhosis.

PATIENTS AND METHODS

Patients and study design

The study population comprised 20 patients (14 men and 6 women aged 28 to 61 years, mean 43.5 years). All patients were anti-HCV positive by second generation ELISA (ORTHO diagnostics, Rariran, New Jersey, USA) and by RIBA-2 for at least 6 months. Written consent was obtained from all patients before the study, which was approved by the Ethics Committee of the Royal Free Hospital School of Medicine, London, England. The study was conducted in accordance with the Declaration of Helsinki.

Serum ALT and AST levels were measured in each patient to ascertain the biochemical activity of the disease. Serum and liver samples for quantitation of HCV RNA were obtained on the same day. Serum was stored at -20°C. The liver samples were collected under strictly sterile conditions. A portion of the biopsy specimen was immediately frozen in liquid nitrogen and stored frozen at -70°C until processed for quantitative HCV RNA assay, whilst the other fragment of the biopsy was processed for histology by routine methods. Liver samples were obtained from 14 patients submitted to percutaneous liver biopsies for diagnosis or clinical management and the remainder from liver explants in patients undergoing orthotopic liver transplantation (OLT).

Methods

HCV RNA measurement:

a) Serum: concentrations of HCV RNA were determined by the quantitative bDNA (version 1) signal amplification assay (Quantiplex HCV RNA assay, Chiron corporation) according to the manufacturer’s instructions. This test is based upon specific hybridisation of virus RNA in the sample by synthetic oligonucleotides to the highly conserved 5-untranslated region and core gene of HCV RNA immobilised on the surface of a microwell plate. Synthetic bDNA amplifier molecules and multiple copies of an alkaline phosphatase-linked probe are hybridised to the immobilised complex. The complex is incubated with a chemo-luminescent substrate and the light emission is measured, the signal being proportional to the level of target nucleic acid. The quantity of HCV RNA in the sample is determined from a standard curve. The detection limit of the test is 350,000 HCV RNA equivalents per mL. These measurements were corrected for possible differences in efficiency of measurement of HCV RNA of different genotypes (16).

b) Liver: the liver sample was weighed and homogenised and RNA was isolated according to the following procedure. The homogenisation was done using pellet pestle mixers and matched tubes to which guanidine HCl (6M) homogenization solution (0.5 mL per 25 mg of tissue or a final volume of 0.5 mL for smaller samples) was added. Sarcosyl (20%) was added in order to obtain a final concentration of 0.5%. After vortexing and holding at 2-8 °C for 5 minutes, the specimen was centrifuged (12,000 G x 1 minute) and the supernatant was collected. Ten microlitres of poly A (10 mg/mL) was added to each tube and the content was gently vortexed. A 0.25 mL amount of 100% ethanol was added to each tube and mixed very thoroughly. The preparation was left to stand at -20°C overnight, centrifuged at 12,000 G for 20 minutes and the supernatant carefully aspirated. An additional amount of 0.5 mL 70% ethanol was added to each tube. The tubes were then vortexed and centrifuged again for 20 minutes. The supernatant was aspirated and the pellet dried down with a rotary vacuum apparatus. The samples were stored at -70°C until processing and from this point, samples were processed in the same way as serum samples.

The results (Eq/gm) were calculated by multiplying the result by the luminometer measurement in Eq/mL by 100 and dividing by the number of mg of the liver biopsy specimen. Corrections for possible differences in efficiency of measurement of HCV RNA of different genotypes were done in a similar way as described for serum samples.
HCV genotyping

Nineteen patients were genotyped by restriction fragment length polymorphism (RFLP)\(^{15}\). The amplicons generated from the 5' non-coding region were digested with restriction enzymes *HaeIII/RsaI* and *BstNI/Hinfl* and the products were analyzed to classify HCV into genotypes.

Statistical analysis

Data were analysed statistically by the Fisher exact test and Mann-Whitney U test and the correlation coefficients were determined.

RESULTS

HCV RNA was detected in 15 of 20 serum specimens and 19 of 20 liver samples by bDNA assay. The weight of the liver samples ranged from 3 to 17 mg (mean ± SD = 5.64 ± 3.67 mg) when the material was collected by percutaneous liver biopsy and from 25 to 29 mg (mean ± SD = 27.8 ± 1.6 mg) when the specimens were obtained from liver explants. The only liver sample showing a negative result for bDNA was obtained by percutaneous biopsy; its weight was 8 mg. This patient was negative for HCV RNA in serum by bDNA as well, but tested positive for HCV RNA by RT-PCR.

The range and mean values of HCV RNA by bDNA assay in serum and liver are shown in Table 1. RNA values were corrected for differences in efficiency of measurement of HCV RNA in types 1-6\(^{19}\). Nineteen patients were genotyped, 12 were infected with HCV type 1, 6 with type 3 and 1 with type 5. No difference was observed between the levels of HCV RNA in serum or liver when comparing HCV type 1 and HCV type 3 (Table 2).

![Figure 1](image-url) – Strong correlation between HCV RNA results by bDNA assay in serum and liver samples \( (P < 0.0001) \). The results of four serum samples below the detection limit of the test were depicted as 3.5x10\(^5\) Eq/mL. HCV genotypes: ● type 1, ○ type 3, ▲ type 5.

Histopathological analysis showed chronic hepatitis in 12 patients and cirrhosis in 8. No difference was observed between cirrhotics and patients with chronic hepatitis regarding HCV RNA levels in the liver however cirrhotic patients showed lower serum HCV RNA concentrations \( (P = 0.001) \) (Table 3).

| TABLE 1 – HCV RNA results by bDNA assay in serum and liver samples |
|------------------------|----------------|-----------------------|---------------------|-----------------|
| **bDNA results** | **n** | **range** | **mean ± SD** |
| Serum (Eq/mL) | 15 | 4x10\(^5\) - 266x10\(^5\) | 94 x 10\(^5\) ± 93 x 10\(^5\) |
| Liver (Eq/gm) | 19 | 0.027x10\(^5\) - 7.46x10\(^5\) | 2.1 x 10\(^5\) ± 2.2 x 10\(^5\) |
| Liver/serum ratio | 15 | 12 - 267 | 54.14 ± 66.23 |
| **n** = number of samples with results above the limit of the test |

| TABLE 2 – HCV RNA results (mean ± SD) by bDNA assay in serum and liver samples according to HCV genotypes |
|------------------------|----------------|-----------------------|---------------------|-----------------|
| **bDNA results** | **HCV type 1** | **HCV type 3** | **P value** |
| Serum (Eq/mL) | 84.2x10\(^5\) ± 85.2x10\(^5\) | 123.1x10\(^5\) ± 121x10\(^5\) | NS |
| Liver (Eq/gm) | 2.5x10\(^4\) ± 2.4x10\(^4\) | 1.7x10\(^4\) ± 2.2x10\(^4\) | NS |
| **n** = number of samples with results above the limit of the test; NS = not significant |

| TABLE 3 – HCV RNA results (mean ± SD) by bDNA assay in serum and liver samples in cirrhotics and in patients with chronic hepatitis |
|------------------------|----------------|-----------------------|---------------------|-----------------|
| **bDNA results** | **cirrhotics** | **chronic hepatitis** | **P value** |
| Serum (Eq/mL) | 22x10\(^5\) ± 34x10\(^5\) | 156x10\(^5\) ± 81.5x10\(^5\) | \( P = 0.001 \) |
| Liver (Eq/gm) | 1.2x10\(^4\) ± 1.6x10\(^4\) | 2.8x10\(^4\) ± 2.5x10\(^4\) | NS |
| Liver/serum ratio | 88.1 ± 87.3 | 24.4 ± 8.1 | \( P = 0.01 \) |
| **n** = number of samples with results above the limit of the test; NS = not significant |

There was a strong and significant correlation \( (r = 0.89; P < 0.0001) \) between serum and liver HCV-RNA levels (Fig. 1).
DISCUSSION

In this study we demonstrated that it is feasible to measure HCV RNA concentrations in small percutaneous liver biopsy samples and there is a strong correlation between serum and liver HCV RNA levels. Our results were true after correction for differences in HCV RNA concentrations obtained using the bDNA (version 1) assay. The results support the hypothesis that serum levels of HCV RNA reflect those in the liver. Similar results were obtained by others(1, 10, 14, 17).

The present results demonstrate that quantitation of HCV RNA in serum provides information about HCV RNA in the liver and suggest that it is not usually necessary to measure hepatic HCV RNA concentrations to stratify treatment approaches. Thus they also support the concept that HCV RNA levels in serum, which reflect viral load in the liver, are valid measurements to predict the response to alpha-interferon therapy and for planning drug treatment. Previous studies have not suggested that hepatic HCV RNA distribution between the right and left lobes of the liver will be a confounding variable(6).

Our study, similarly to others (1, 10, 14, 17), has shown a significantly higher concentration of HCV RNA in liver tissue compared to serum. In view of this, measurement of serum viral load is representative of hepatic HCV RNA viral load albeit extrahepatic sites of replication may also contribute.

We did not observe any correlation between ALT and AST levels in the serum and HCV RNA levels in serum or liver.

Lower serum HCV RNA concentrations were observed in patients with cirrhosis in the liver biopsy. However, hepatic HCV RNA concentrations did not differ between cirrhosis and chronic hepatitis. It should be stressed, however, that the number of patients was relatively small, and the significance of this finding should be confirmed. A study of HCV RNA levels in liver samples with different degrees of severity of lesions may help to clarify the mechanisms involved in hepatocellular injury.

In conclusion, serum HCV RNA levels reflect liver HCV RNA levels, so that both can be used successfully in the management of patients with chronic HCV infection and to monitor their response to antiviral therapy. The strong correlation between serum and hepatic levels supports the employment of serum measurements, as they are more practical.

ACKNOWLEDGEMENTS

We are grateful to Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Apoio ao Ensino e Pesquisa e Assistência (FAEPA) of the University Hospital of FMRP-USP for financial support.
REFERENCES


